NEWS: Medicare proposes covering expensive drug for early-stage Alzheimer's - but with restrictions
Published in the Washington Post by Laurie McGinley and Amy Goldstein January 11, 2022
"Medicare officials announced Tuesday they would cover a controversial Alzheimer's drug - but only with restrictions that will sharply limit who receives the drug. The Centers for Medicare and Medicaid Services proposed a national policy that would cover Aduhelm and similar drugs in development only for people enrolled in qualifying clinical trials.
The proposal is open to public comment for 30 days. The agency has said it plans to issue a final decision in April. The draft decision, if finalized, would apply to monoclonal antibodies approved by the Food and Drug Administration that target amyloid, a sticky substance that can build up in the brain."